Author

H. Baik

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Organism:mouse· 1 Research Focus:protein structure prediction· 1

Frequent Co-Authors

G. Bossis· 2 shared G. Cartron· 2 shared J.-E. Sarry· 2 shared M. Boulanger· 2 shared M. Piechaczyk· 2 shared A. Bykov· 1 shared A. Dupanovic· 1 shared A. R. Poetsch· 1 shared

Activity by Year

2018-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

G. Bossis

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Natural killer cell cytotoxicity shapes the clonal evolution of B cell leukaemia

M. C. Buri, M. R. Shoeb, A. Bykov, P. Repiscak, H. Baik, A. Dupanovic, F. O. David, B. Kovacic, F. Hall-Glenn, S. Dopa, J. Urbanus, L. Sippl, S. Stofner, D. Emminger, J. Cosgrove, , E. M. Putz

This study shows NK cells influence all phases of cancer immunoediting in B-ALL, promoting resistant clones through selective pressure and identifying LY6E as a marker of poor prognosis.

bioRxiv · Nov 16, 2023Cancer Biology

The NADPH oxidase NOX2 is a marker of adverse prognosis involved in chemoresistance of Acute Myeloid Leukemias

R. Paolillo, M. Boulanger, P. Gatel, L. Gabellier, D. Tempe, R. Hallal, M. De Toledo, J. Moreaux, H. Baik, E. Gueret, C. Recher, J.-E. Sarry, G. Cartron, M. Piechaczyk, G. Bossis

This study identifies NOX2 as a marker of poor prognosis and a contributor to chemoresistance in AML, showing its upregulation in drug-resistant cells and association with adverse outcomes.

bioRxiv · Mar 4, 2021Cancer Biology

Targeting the SUMO pathway primes all-trans-retinoic acid-induced differentiation of non promyelocytic Acute Myeloid Leukemias

H. Baik, M. Boulanger, M. Hosseini, J. Kowalczyk, S. Zaghdoudi, T. Salem, J.-E. Sarry, Y. Hicheri, G. Cartron, M. Piechaczyk, g. bossis

This study shows that inhibiting the SUMO pathway enhances the effectiveness of all-trans-retinoic acid in treating non-APL AMLs by promoting differentiation and reducing proliferation.

bioRxiv · Jan 29, 2018Cancer Biology